Selected research
Industry Research
Ustekinumab Biosimilars Industry Research Report 2026
Market perspective
The global Ustekinumab Biosimilars market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Ustekinumab Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Ustekinumab Biosimilars is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Ustekinumab Biosimilars is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Ustekinumab Biosimilars include Teva, Amgen, Samsung Bioepis, Sandoz, Biocon Biologics, Celltrion, Qyuns Therapeutics, Bio-Thera Solutions and Huadong Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Ustekinumab Biosimilars market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Ustekinumab Biosimilars Market by Company
Teva
Amgen
Samsung Bioepis
Sandoz
Biocon Biologics
Celltrion
Qyuns Therapeutics
Bio-Thera Solutions
Huadong Medicine
Ustekinumab Biosimilars Segment by Type
Subcutaneous Injection
Intravenous Infusion
Ustekinumab Biosimilars Segment by Application
Crohn's Disease
Ulcerative Colitis
Plaque Psoriasis
Psoriatic Arthritis
Other
Ustekinumab Biosimilars Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ustekinumab Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ustekinumab Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ustekinumab Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Ustekinumab Biosimilars manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Ustekinumab Biosimilars by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Ustekinumab Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Subcutaneous Injection
- Intravenous Infusion
Applications
- Crohn's Disease
- Ulcerative Colitis
- Plaque Psoriasis
- Psoriatic Arthritis
- Other
Companies covered
- Teva
- Amgen
- Samsung Bioepis
- Sandoz
- Biocon Biologics
- Celltrion
- Qyuns Therapeutics
- Bio-Thera Solutions
- Huadong Medicine
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Ustekinumab Biosimilars Market Size (2021-2032)
- 2.2.2 Global Ustekinumab Biosimilars Sales (2021-2032)
- 2.2.3 Global Ustekinumab Biosimilars Market Average Price (2021-2032)
- 2.3 Ustekinumab Biosimilars by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Subcutaneous Injection
- 2.3.3 Intravenous Infusion
- 2.4 Ustekinumab Biosimilars by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Crohn's Disease
- 2.4.3 Ulcerative Colitis
- 2.4.4 Plaque Psoriasis
- 2.4.5 Psoriatic Arthritis
- 2.4.6 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Ustekinumab Biosimilars Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Ustekinumab Biosimilars Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Ustekinumab Biosimilars Revenue of Manufacturers (2021-2026)
- 3.4 Global Ustekinumab Biosimilars Average Price by Manufacturers (2021-2026)
- 3.5 Global Ustekinumab Biosimilars Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Ustekinumab Biosimilars, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Ustekinumab Biosimilars, Product Type & Application
- 3.8 Global Manufacturers of Ustekinumab Biosimilars, Established Date
- 3.9 Global Ustekinumab Biosimilars Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Ustekinumab Biosimilars Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Amgen
- 4.2.1 Amgen Company Information
- 4.2.2 Amgen Business Overview
- 4.2.3 Amgen Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Amgen Ustekinumab Biosimilars Product Portfolio
- 4.2.5 Amgen Recent Developments
- 4.3 Samsung Bioepis
- 4.3.1 Samsung Bioepis Company Information
- 4.3.2 Samsung Bioepis Business Overview
- 4.3.3 Samsung Bioepis Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Samsung Bioepis Ustekinumab Biosimilars Product Portfolio
- 4.3.5 Samsung Bioepis Recent Developments
- 4.4 Sandoz
- 4.4.1 Sandoz Company Information
- 4.4.2 Sandoz Business Overview
- 4.4.3 Sandoz Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sandoz Ustekinumab Biosimilars Product Portfolio
- 4.4.5 Sandoz Recent Developments
- 4.5 Biocon Biologics
- 4.5.1 Biocon Biologics Company Information
- 4.5.2 Biocon Biologics Business Overview
- 4.5.3 Biocon Biologics Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Biocon Biologics Ustekinumab Biosimilars Product Portfolio
- 4.5.5 Biocon Biologics Recent Developments
- 4.6 Celltrion
- 4.6.1 Celltrion Company Information
- 4.6.2 Celltrion Business Overview
- 4.6.3 Celltrion Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Celltrion Ustekinumab Biosimilars Product Portfolio
- 4.6.5 Celltrion Recent Developments
- 4.7 Qyuns Therapeutics
- 4.7.1 Qyuns Therapeutics Company Information
- 4.7.2 Qyuns Therapeutics Business Overview
- 4.7.3 Qyuns Therapeutics Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Qyuns Therapeutics Ustekinumab Biosimilars Product Portfolio
- 4.7.5 Qyuns Therapeutics Recent Developments
- 4.8 Bio-Thera Solutions
- 4.8.1 Bio-Thera Solutions Company Information
- 4.8.2 Bio-Thera Solutions Business Overview
- 4.8.3 Bio-Thera Solutions Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bio-Thera Solutions Ustekinumab Biosimilars Product Portfolio
- 4.8.5 Bio-Thera Solutions Recent Developments
- 4.9 Huadong Medicine
- 4.9.1 Huadong Medicine Company Information
- 4.9.2 Huadong Medicine Business Overview
- 4.9.3 Huadong Medicine Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Huadong Medicine Ustekinumab Biosimilars Product Portfolio
- 4.9.5 Huadong Medicine Recent Developments
5 Global Ustekinumab Biosimilars Market Scenario by Region
- 5.1 Global Ustekinumab Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Ustekinumab Biosimilars Sales by Region: 2021-2032
- 5.2.1 Global Ustekinumab Biosimilars Sales by Region: 2021-2026
- 5.2.2 Global Ustekinumab Biosimilars Sales by Region: 2027-2032
- 5.3 Global Ustekinumab Biosimilars Revenue by Region: 2021-2032
- 5.3.1 Global Ustekinumab Biosimilars Revenue by Region: 2021-2026
- 5.3.2 Global Ustekinumab Biosimilars Revenue by Region: 2027-2032
- 5.4 North America Ustekinumab Biosimilars Market Facts & Figures by Country
- 5.4.1 North America Ustekinumab Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Ustekinumab Biosimilars Sales by Country (2021-2032)
- 5.4.3 North America Ustekinumab Biosimilars Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Ustekinumab Biosimilars Market Facts & Figures by Country
- 5.5.1 Europe Ustekinumab Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Ustekinumab Biosimilars Sales by Country (2021-2032)
- 5.5.3 Europe Ustekinumab Biosimilars Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Ustekinumab Biosimilars Market Facts & Figures by Country
- 5.6.1 Asia Pacific Ustekinumab Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Ustekinumab Biosimilars Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Ustekinumab Biosimilars Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Ustekinumab Biosimilars Market Facts & Figures by Country
- 5.7.1 South America Ustekinumab Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Ustekinumab Biosimilars Sales by Country (2021-2032)
- 5.7.3 South America Ustekinumab Biosimilars Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Ustekinumab Biosimilars Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Ustekinumab Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Ustekinumab Biosimilars Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Ustekinumab Biosimilars Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Ustekinumab Biosimilars Sales by Type (2021-2032)
- 6.1.1 Global Ustekinumab Biosimilars Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Ustekinumab Biosimilars Sales Market Share by Type (2021-2032)
- 6.2 Global Ustekinumab Biosimilars Revenue by Type (2021-2032)
- 6.2.1 Global Ustekinumab Biosimilars Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Ustekinumab Biosimilars Revenue Market Share by Type (2021-2032)
- 6.3 Global Ustekinumab Biosimilars Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Ustekinumab Biosimilars Sales by Application (2021-2032)
- 7.1.1 Global Ustekinumab Biosimilars Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Ustekinumab Biosimilars Sales Market Share by Application (2021-2032)
- 7.2 Global Ustekinumab Biosimilars Revenue by Application (2021-2032)
- 7.2.1 Global Ustekinumab Biosimilars Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Ustekinumab Biosimilars Revenue Market Share by Application (2021-2032)
- 7.3 Global Ustekinumab Biosimilars Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Ustekinumab Biosimilars Value Chain Analysis
- 8.1.1 Ustekinumab Biosimilars Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Ustekinumab Biosimilars Production Mode & Process
- 8.2 Ustekinumab Biosimilars Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Ustekinumab Biosimilars Distributors
- 8.2.3 Ustekinumab Biosimilars Customers
9 Global Ustekinumab Biosimilars Analyzing Market Dynamics
- 9.1 Ustekinumab Biosimilars Industry Trends
- 9.2 Ustekinumab Biosimilars Industry Drivers
- 9.3 Ustekinumab Biosimilars Industry Opportunities and Challenges
- 9.4 Ustekinumab Biosimilars Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst